Navigation Links
Study opens new prospects for developing new targeted therapies for breast cancer
Date:5/2/2013

t rate versus placebo plus exemestane. Although benefits were seen in all prospectively defined subgroups of women who took part, the researchers noted some variations, partially due to genetic differences in molecular determinants of everolimus sensitivity and interactions between the oestrogen receptor and mTOR pathways.

In the current analysis, researchers used next-generation sequencing to assess genetic alterations in archival tumour specimens from 230 tumours. They analysed coding regions of 182 cancer-related genes for sequence and copy number variations.

All patients had at least one genetic alteration, and 98% had more than 2, the researchers report. A total of 173 different genes were altered in at least one of the tumour samples. Among the frequently mutated genes were PIK3CA, TP53 and ARID1A.

"Some mutations were found to cluster into similar pathways, for which targeted therapies could potentially be used," Dr Piccart said.

"Although in many cases we cannot be sure what effect the mutations have on the tumour characteristics or the clinical efficacy of treatments, we did find that mutations in the tumour suppressor gene PTEN were associated with loss of protein expression and function."

The authors also found an increased mutation rate for the oestrogen receptor, a key player in breast cancer, between primary and metastatic samples, which highlights potentially clinically relevant differences between the primary and metastatic disease for this group of hormone-receptor positive patients.

More generally, the results illustrate that this kind of sequencing is feasible in phase III studies, the researchers say.

"The ability to carry on large-scale sequencing in phase III trials will potentially help us understand why some patients did show a good clinical response to the investigated drugs whereas others did not. Also, being able to sequence cancer genes in well-described clinically homogeneous cohorts of clinical trials w
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... NEW YORK , Nov. 13, 2014  While we ... of technology Doctor McCoy used in "Star Trek" to gain ... and tools designed to work with smartphones and tablets for ... corners of the healthcare world. This may seem a tad ... are ready to adopt some of these technological opportunities into ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
(Date:11/7/2014)... , November 6, 2014 Leading Biometric ... better mobile security revolutionizing online transactions.  Companies in focus today ... Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... eBay Inc. (NASDAQ: EBAY ) and MasterCard Inc. ... and NXTDW), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... MINNEAPOLIS / ST. PAUL (03/05/2013) Have agriculture, technology, diet and ... we evolved? And would we be healthier and happier if ... Paleolithic ancestors did? The abundance of Paleo diet and ... Minnesota evolutionary biologist Marlene Zuk is skeptical. The Paleo ideal ...
... University of Florida paleontologists have discovered remarkably well-preserved fossils ... science during recent Panama Canal excavations that began in ... and an extinct hippo-like species inhabited Central America during ... expands the range of ancient animals in the subtropics ...
... the use of a component of green algae ... of the Ligon Research Center of Vision at the ... to RetroSense Therapeutics, a biotechnology company dedicated to developing ... U.S. Patent and Trademark Office has issued a Notice ...
Cached Biology News:The way we weren't: U of Minnesota biologist debunks myth that humans peaked in Paleolithic era 2UF scientists discover new crocodilian, hippo-like species from Panama 2UF scientists discover new crocodilian, hippo-like species from Panama 3Wayne State vision restoration technology receives Notice of Allowance for US patent app 2
(Date:11/24/2014)... Senior Vice President, General Manager for Clinical ... acumen Elsevier , a world-leading provider ... congratulates Diane Bartoli , Senior Vice President and ... Solutions, for being recognized in the 13 th ... Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... 2014 Two new educational webinars hosted by ... for ALS research and how the pharmaceutical industry can make ... Bucket Challenge: Where Does the ALS Money Go? , Featuring ... 2014, Time: 1:30pm ET, Register to attend , ... Merit Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General ...
(Date:11/22/2014)... Prominent academics, leaders of the ... December 3rd at Genetic Rx, a networking conference ... take place at the Joseph B. Martin Conference ... the present and future of genetic medicines—including siRNA, ... editing—as well as the treatment of patients with ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2
... to $7.7 million ... Quarter Net Income Increased 67.5% to $1.7 million, - First Six Months Revenues Increased 82% to ... 65% to $3.2 million for the Same Period, - Growth Driven by New Distribution ... ...
... IRVINE, Calif., Feb. 14 SectorWatch.biz announces the,availability ... the news and,driving markets today., Investors can ... by,visiting: http://www.SectorWatch.biz -- Click on MarketStats, ... include:,CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today ... results on Wednesday, February 20, 2008, after the,U.S. financial ... and webcast to discuss its fourth,quarter and year-end 2007 ... Wednesday, February 20, 2008 at 5:00 p.m. Eastern,Standard Time. ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 8SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results 2
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
3M Imidazole Solution 125 ml...
Biology Products: